68 results about "Cellular Assay" patented technology

We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for a detectable characteristic of interest (e.g., presence of an analyte). By employing multiple distinct DCB labels at varying concentrations, one can perform multiplex analyses on up to hundreds or thousands (or more) of cell samples in a single reaction tube. DCB reduces reagent consumption by factors of 100-fold or more, significantly reduces data acquisition times and allows for stringent control sample analysis.

Disclosed herein are methods for single-cell sequencing. In some examples, the methods include enriching a sample comprising a plurality of cells for cells of interest to produce an enriched cell sample; isolating one or more cells of interest in the enriched cell sample; and obtaining sequence information of one or more polynucleotides from each of the one or more isolated cells. Obtaining sequence information may include generating a molecularly indexed polynucleotide library from the one or more isolated cells. Enriching the sample may include focusing cells of interest in the sample using acoustic focusing.

The present invention includes devices, systems, and methods for assaying cells using cell-substrate impedance monitoring. In one aspect, the invention provides cell-substrate impedance monitoring devices that comprise electrode arrays on a nonconducting substrate, in which each of the arrays has an approximately uniform electrode resistance across the entire array. In another aspect, the invention provides cell-substrate monitoring systems comprising one or more cell-substrate monitoring devices comprising multiple wells each having an electrode array, an impedance analyzer, a device station that connects arrays of individual wells to the impedance analyzer, and software for controlling the device station and impedance analyzer. In another aspect, the invention provides cellular assays that use impedance monitoring to detect changes in cell behavior or state. In some preferred aspects, the assays are designed to investigate the affects of compounds on cells, such as cytotoxicity assays. In other preferred aspects, the assays are designed to investigate the compounds that effect IgE-mediated responses of cells to antigens.

High throughput and automated cellular disruption systems that substantially uniformly disrupt cells as part of cellular motility assays as wells as other assay types are provided. In addition, various system components, including holding blocks, holding block loading devices, and system software, are also provided. Moreover, related methods that utilize these systems and system components are additionally provided.

The present invention relates to the field of molecular diagnostics, and in particular to diagnostics based on a liquid crystal assay format. In particular, the present invention provided improved substrates and methods of using liquid crystal assays for quantitating the amount of an analyte in a sample. The present invention also provides materials and methods for detecting non-specific binding of an analyte to a substrate by using a liquid crystal assay format.

The invention discloses a series drugs for resisting novel coronavirus SARS-CoV-2 and application thereof. In-vitro cell test results show that compounds disclosed in the invention can significantly inhibit infection of SARS-CoV-2 on normal cells, have an inhibition effect on novel coronavirus SARS-CoV-2 at a cellular level, can significantly reduce the virus titer of novel coronavirus in cells and inhibit proliferation of the novel coronavirus in cells, and has dose dependence. Therefore, the compounds can be used as inhibitors for novel coronavirus SARS-CoV-2, and has the potential of treating COVID-19 pneumonia caused by infection of a human body with the coronavirus SARS-CoV-2 or other diseases caused by infection of animals with the coronavirus SARS-CoV-2.

The invention discloses an application of GC376 in preparation of a novel coronavirus SARS-CoV-2 inhibitor. In-vitro cell test results prove that GC376 can notably inhibit infection of SARS-CoV-2 on normal cells, has an inhibition function on SARS-CoV-2 in terms of cell level, can notably reduce toxicity of the virus in cells and inhibit proliferation of the virus in the cells and is dose-dependent. Therefore, GC376 can serve as the novel coronavirus SARS-CoV-2 inhibitor and has the potential of treating COVID-19 caused by the virus or other diseases caused after animals are infected.

In one aspect, the present invention relates to a system 100 for automated cellular assay data analysis. The system 100 comprises a virtual assay module (VAM) 115 operable to generate simulated images of cell responses to one or more stimuli. The system 100 also comprises a comparator module 116 operable to compare the actual and simulated images, and an analysis module 117 operable to quantify the differences between phenotypes represented by the actual and simulated images. Various aspects and embodiments of present invention may account for stochastic variations in the response of single cells, to provide additional useful information relating to, for example, toxological effects and/or for use as part of a feedback mechanism to refine dynamically a virtual assay model such that it is not limited by way of there being only inadequate static fitting expressions available.

The present invention relates to cryopreserved cell cultures, methods for cryopreserving cells and methods for conducting cellular assays on such cells. A cryopreserved cell culture of the invention comprises a container having at least a surface which is coated with poly-lysine and frozen cells supported on the surface.

The present invention concerns a tester protein for identifying and/or monitoring protease activity in a cellular assay suitable for high throughput screenings by growth selection, wherein the tester polypeptide is a non-regulatory protein carrying a protease cleavage sequence. Upon co-expression of the protease recognizing said cleavage sequence the tester protein is inactivated, which influences the growth and/or survival of the host cells under the chosen conditions. However, in the presence of protease inhibitor the growth phenotype is reversed. The system can be used to identify proteases, protease inhibitors, and protease cleavage sites.

This invention relates to the field of biological assays where cells can be classified and enumerated using flow cytometry optical instrumentation. The invention combines information from multi-angle, light scatter from the cell itself and multi-angle light scatter from small, optically resonant particles that are selectively bound to surface molecules on the cell to carry out classification and enumeration. This light scatter method enables an instrumentation system that is simple to use, inexpensive to build, and mechanically robust; making it suitable for use in remote clinical environments.

The present invention relates generally to the fields of molecular biology and cancer. More specifically, the invention concerns methods and compositions useful for diagnosing and assessing a subject's response to therapy.

The invention discloses a pharmaceutical composition. The pharmaceutical composition is composed of GC376 and GS-441524. In-vitro cell test results show that the composition can inhibit proliferationof novel coronavirus SARS-CoV-2 in cells, has a better drug effect than a single drug, has a significant synergistic effect, can be used as a novel coronavirus SARS-CoV-2 inhibitor, is used for treating COVID-19 pneumonia, and has the advantages of good curative effect, high safety, no toxic or side effects, capability of reducing drug resistance of viruses and toxic and side effects of drugs, etc.

The invention relates to an injector which is installed on an automatic cell sedimentation tablet compressing machine and conducts rapid abstraction and push on the liquid sample of cast-off cells that contain rather much mucilage. The injector is characterized in that a plug is inserted into the needle tube of the injector and provided with at least two groove channels which are internally communicated with the tube of the injector. The injector can abstract and push sample more rapidly, the sample does not spill over and the channel is not blocked completely, thus being conducive to realizing automation. A mould used for manufacturing the utility model is simple and the assembly of semi-manufactured goods is convenient; therefore, the injector which has low cost and is disposable to prevent crossing contamination can be manufactured on a large scale.

The invention belongs to the technical field of medicine preparation, and particularly relates to application of a PI3K inhibitor NVP-BYL719 for preparing a COVID-19 inhibitor. An in vitro cell test result indicates that the medicine can inhibit the proliferation of the COVID-19 in cells. Meanwhile, a mouse challenge test result indicates that the medicine can effectively lower the lung viral loadof an infected mouse, has an obvious treatment function for the infected mouse, can be used as the COVID-19 inhibitor and is used for treating the COVID-19 pneumonia.